Rangers board changes made official as trio stand down
The exits of Johnston, Park and Wolhardt have been officially confirmed in an update on Companies House, all three having their appointments terminated.
Cavenagh takes over from Fraser Thornton as chairman but the latter will continue to be part of the board.
Read more:
Paarag Marathe is the new vice-chairman.
John Halsted and George Taylor remain on the board as directors and chief executive Patrick Stewart stays in his role.
New board member Taber is managing director at Great Hill Partners, a growth equity firm based in Boston.
He specialises in healthcare investments and has been on the boards of over a dozen healthcare companies.
He is also a trustee of Boston Medical Centre's HealthNet health plan and a member of its finance committee.
Clayton is the co-founder and vice-chairman of ParetoHealth, a health insurance company founded by Cavenagh.
Schneur, a board member and co-owner of Leeds United, is the third new face.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
FDA lifts pause on vaccine against chikungunya virus spreading from China
The FDA has lifted a pause on the administration of a vaccine for the chikungunya virus, a mosquito-borne illness currently spreading from China . The Ixchiq single-dose vaccine was approved for adults 18 and up at risk of exposure to the virus in 2023, when the CDC had recorded 152 travel-associated cases of the virus, the highest rate in four years. But administrations of the shot to adults aged 60 and older were paused in May of this year, triggered by reports of 17 serious side effects following vaccination, including two deaths. Most of the reported issues were neurological or cardiac, and all involved people over 60. Six cases were reported in the US , with the remaining cases among the tens of thousands of people vaccinated worldwide. However, on August 7, the FDA greenlit the vaccine again for adults 60 and up. While the agency did not say whether the lifted pause is related to an uptick in infections, the chikungunya virus is spreading globally. Cases are currently rising in China, with more than 10,000 recorded, and the virus is spreading to nearby countries, as well as Europe. As of August 5, the CDC reports 46 cases of chikungunya virus in the US this year, all contracted by travelers returning from high-risk areas. No deaths have been reported. The CDC recommends Americans traveling to high-risk chikungunya countries receive one of the two FDA-approved vaccines. However, the FDA changed its guidelines from recommending the shot to travelers and scientists at 'increased risk' to those at 'high risk.' An FDA spokesperson told 'FDA has completed an updated benefit-risk assessment of Ixchiq, including for use in individuals 18 years of age and older. 'Based on the available data and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in individuals 60 years of age and older.' While there's no specific number for how many Americans have been vaccinated for chikungunya, it's known that around 43,000 people have received the vaccine globally. The reported adverse reactions to the Ixchiq vaccine included severe headaches, dizziness, intense nerve pain, trouble with balance, fainting, extreme muscle aches, and severe joint and back pain. The virus, meanwhile, causes flu-like symptoms within three to seven days of being bitten by a mosquito. A high fever is typical, as is joint pain in the hands, wrists, ankles and knees. It also causes muscle pain, fatigue, nausea and vomiting, swollen joints and swollen lymph nodes. Joint damage can be severe and long-lasting, potentially for years. Deaths are rare, but certain groups can experience life-threatening illness. Newborns, the elderly, and people with chronic health conditions, including obesity and diabetes, are more susceptible to seizures and brain swelling, heart problems, and kidney or liver damage. While the vaccine's labeling has been changed to stipulate that only people at high risk of exposure should get the shot, limitations of use have been added. The labeling now says: 'Vaccination with Ixchiq is not advisable for most US travelers. For most US travelers, the risk of exposure to CHIKV is low. 'The decision to administer Ixchiq should take into consideration an individual's risk of severe or chronic disease outcomes if infected with CHIKV and risks of serious, severe, or prolonged chikungunya-like illness caused by vaccination with Ixchiq.' The European vaccine company Valneva developed Ixchiq, the first-ever vaccine to prevent the chikungunya virus, in 2023. But the shot has been plagued by reports of more than a dozen serious adverse events, including two deaths, in adults 62 to 89. The European Medicines Agency suspended its use in May and the FDA soon followed. A second chikungunya vaccine, Vimkunya, was approved by the FDA in February 2025. The Ixchiq vaccine contains a weakened form of the virus, which may cause symptoms of chikungunya. Federal officials said some of the severe adverse events reported are similar to severe complications from the disease. According to Valneva, the FDA has received its petition to expand its availability to teenagers. Chikungunya spreads through bites from the Aedes mosquito species, typically in countries where the virus is common, primarily those in Africa and Asia. Twelve Americans were infected within US borders in 2014, while one infection was acquired in 2015. Since then, all US infections have been contracted abroad. There have been about 220,000 Chikungunya virus cases and 80 related deaths in 14 countries since the beginning of 2025, according to the European Center for Disease Prevention and Control. While it remains unclear in which countries American patients contracted the virus, the federal government has issued an elevated risk of exposure notice for Brazil, China Colombia, India, Mexico, Nigeria, Pakistan, Philippines and Thailand.
Telegraph
3 hours ago
- Telegraph
Mike Lynch ally plots comeback after serving prison sentence
The former finance chief at Mike Lynch's software company Autonomy is planning a comeback after returning from a US prison sentence. Sushovan Hussain has recently set up a company called Liberatus to help former criminals return to the workforce. Mr Hussain, 61, spent three and a half years in US prison in Pennsylvania after being found guilty of fraud over the £7bn sale of Autonomy. He was released last year. Mr Lynch was cleared of his own fraud charges. He died while celebrating his freedom in the sinking of the Bayesian superyacht a year ago. Mr Hussain said that when he returned to the UK he had experienced similar problems to many ex-offenders who often struggle to open bank accounts and obtain IDs. He said helping people back into work would help cut the number of people reoffending, easing pressure on Britain's overcrowded prisons. Companies House records show Mr Hussain set up and owns Liberatus – Latin for 'freed' – with his wife, Tracie. The company has also recruited former staff from Autonomy and Darktrace, the cyber security company Mr Hussain set up with Mr Lynch. The company will be an employment agency for people with criminal records to find temporary work. It is planning a trial in Cambridge before planning to expand across the country. Mr Hussain's plans could receive support from Lord Timpson, the prisons minister, who has pushed for more employers to hire ex-offenders. 'Over 50pc of ex-offenders reoffend within 12 months – primarily because reintegrating into society is extraordinarily difficult,' Mr Hussain said. 'Securing employment with a criminal record remains one of the most significant barriers. However, we know that for those who do find work, the reoffending rate drops to below 5pc. 'After returning to the UK from a period in US federal prison in 2024, I experienced first-hand the challenges faced by those with a record. 'I'm fortunate to be able to navigate the system in ways others can't and now I want to help those who are less able to advocate for themselves.' 'Win-win' As Autonomy's chief financial officer, Mr Hussain was Mr Lynch's right-hand man. After Hewlett-Packard claimed they had been defrauded over the software company's purchase, Mr Hussain was charged and found guilty on 16 counts of fraud in 2018, entering prison after losing an appeal in 2020. He was released in early 2024, months before Mr Lynch and finance director Stephen Chamberlain secured shock acquittals. This year he settled a UK civil case brought by HP against him and Mr Lynch. A judge later ruled that damages amounted to more than £740m, a sum that threatens to wipe out Mr Lynch's estate. Before his death, Mr Lynch had separately mused about funding a UK version of the Innocence Project, which would finance legal defences for wrongly accused Britons. He had also planned to investigate the Lucy Letby case, according to the Conservative MP David Davis, who knew him well. Lord Timpson this year set up employment councils featuring major employers in an attempt to encourage more former criminals into the workforce. Mr Hussain said: 'I echo Lord Timpson's words: this is a 'win-win situation we cannot ignore.''
Reuters
3 hours ago
- Reuters
Wall St set for muted open as chip stocks dip on China sales deal
Aug 11 (Reuters) - Wall Street was on track for a subdued start on Monday as major chip companies slipped on the eve of a key tariff deadline after a trade policy shift that involves sharing a portion of revenue from China sales with the Trump administration. Semiconductor giant Nvidia (NVDA.O), opens new tab slipped 0.4% in premarket trading, while Advanced Micro Devices (AMD.O), opens new tab lost 1.2%. A U.S. official told Reuters the companies had agreed to give the United States government 15% of revenue from sales of their advanced computer chips to China, days after the Commerce Department began issuing licenses for the sale of Nvidia's H20 chips. Enabling semiconductor sales to China was an integral issue in the agreement Washington signed with Beijing earlier this year and markets will be keen to know if the latest development will impact the relationship between the world's two largest economies. The deal expires on Tuesday. "It's a good way for the United States government to increase its cash and income... but a lot of people are going to argue that this is the wrong way to go," said Robert Pavlik, senior portfolio manager at Dakota Wealth. "The Chinese government will probably use it as a point to argue that they need different chips because these particular chips might be susceptible to be reviewed by the Americans." Markets also sought clarity on the sector tariffs U.S. President Donald Trump has announced. At 08:48 a.m. ET, Dow E-minis were up 64 points, or 0.14%, S&P 500 E-minis were up 4.75 points, or 0.07%, and Nasdaq 100 E-minis were up 8.5 points, or 0.04%. Traders took a step back after last week's rally helped the S&P 500 (.SPX), opens new tab and the Nasdaq (.IXIC), opens new tab log their strongest weekly performance in more than a month. Investors expect that the recent shake-up at the U.S. Federal Reserve and signs of labor market weakness could nudge the central bank into adopting a dovish monetary policy stance later this year, fueling much of the optimism. July's consumer inflation report is due on Tuesday and investors currently anticipate that the Fed will lower borrowing costs by about 60 basis points by December, according to data compiled by LSEG. A better-than-feared earnings season brought some relief and BofA's monthly fund manager survey showed that owning megacap stocks was again the most popular trade. Apple (AAPL.O), opens new tab was a standout last week following its biggest weekly showing in five years after the iPhone maker unveiled a series of U.S. investment pledges. The company's shares were down 0.5% on Monday. In earnings, Micron (MU.O), opens new tab raised its forecast for fourth-quarter revenue and adjusted profit, reflecting strong demand for artificial intelligence and sending shares of the chip company up 5.1%. U.S.-listed shares of lithium producers rose. Albemarle (ALB.N), opens new tab and Lithium Americas gained more than 10% each after Chinese battery giant Contemporary Amperex Technology (CATL) ( opens new tab halted output at a major mine, raising hopes that it would erode the oversupply in a market grappling with soft demand. Intel (INTC.O), opens new tab was up 2.7% after a report said CEO Lip-Bu Tan was expected to visit the White House. Trump had called for his removal last week. Trump is expected to meet Russia's President Vladimir Putin on Friday to try and negotiate an end to the war on Ukraine.
